 |
23 Products |  |
29 Diseases | | 23 Products |
|
30 Trials |  |
406 News |  |
| «1234 |
- ||||||| Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
Trial completion: Efficacy, Tolerability and Safety of NVA237 in Patients With Chronic Obstructive Pulmonary Disease (clinicaltrials.gov) - Jan 5, 2015
P3, N=773, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed
- Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
Enrollment change, Trial withdrawal: Study of Efficacy and Safety of NVA237 in Patients With Poorly Controlled Asthma (clinicaltrials.gov) - Oct 31, 2014
P3, N=0, Withdrawn, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed N=1938 --> 0 | Not yet recruiting --> Withdrawn
- | Tudorza (aclidinium bromide) / Almirall, Covis Pharma, Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
Trial completion: Acute Effect of Aclidinium on Hyperinflation and Ventilation Inhomogeneity in Severe COPD Patients (clinicaltrials.gov) - Oct 30, 2014
P4, N=37, Completed, Sponsor: University of Milan
N=1938 --> 0 | Not yet recruiting --> Withdrawn Recruiting --> Completed
- ||||| Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
Trial initiation date, Trial primary completion date: Study of Efficacy and Safety of NVA237 in Patients With Poorly Controlled Asthma (clinicaltrials.gov) - Oct 10, 2014
P3, N=1938, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed Initiation date: Oct 2014 --> Mar 2015 | Trial primary completion date: Dec 2016 --> May 2017
- Tudorza (aclidinium bromide) / Almirall, Covis Pharma, Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
New P4 trial: Acute Effect of Aclidinium on Hyperinflation and Ventilation Inhomogeneity in Severe COPD Patients (clinicaltrials.gov) - Jul 4, 2014
P4, N=46, Recruiting, Sponsor: University of Milan
- |||| Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
Trial completion: Efficacy of NVA237 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD) (clinicaltrials.gov) - May 21, 2014
P4, N=152, Completed, Sponsor: Novartis Pharmaceuticals
Initiation date: Oct 2014 --> Mar 2015 | Trial primary completion date: Dec 2016 --> May 2017 Recruiting --> Completed
- ||| hyzetimibe (HS-25) / Zhejiang Hisun
Enrollment closed: A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia (clinicaltrials.gov) - May 19, 2014
P2, N=360, Active, not recruiting, Sponsor: Zhejiang Hisun Pharmaceutical Co. Ltd.
Recruiting --> Completed Recruiting --> Active, not recruiting
- |||| hyzetimibe (HS-25) / Zhejiang Hisun
Enrollment open: A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia (clinicaltrials.gov) - May 4, 2014
P2, N=360, Recruiting, Sponsor: Zhejiang Hisun Pharmaceutical Co. Ltd.
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- |||||||||| Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
New P3 trial: Study of Efficacy and Safety of NVA237 in Patients With Poorly Controlled Asthma (clinicaltrials.gov) - Apr 29, 2014
P3, N=1938, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- Avastin (bevacizumab) / Roche, firtecan pegol (PEG-SN38) / Belrose
Trial completion, Combination therapy: EZN-2208 (Pegylated SN-38) in Combination With Bevacizumab in Refractory Solid Tumors (clinicaltrials.gov) - Apr 23, 2014
P1, N=12, Completed, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||||| hyzetimibe (HS-25) / Zhejiang Hisun
New P2 trial: A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia (clinicaltrials.gov) - Mar 12, 2014
P2, N=360, Not yet recruiting, Sponsor: Zhejiang Hisun Pharmaceutical Co. Ltd.
- ||||||| Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
Trial completion: NVA237 BID Versus Placebo Twelve-week Efficacy Study (clinicaltrials.gov) - Feb 6, 2014
P3, N=432, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Recruiting --> Completed
- ||||| Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
Enrollment closed: Efficacy, Tolerability and Safety of NVA237 in Patients With Chronic Obstructive Pulmonary Disease (clinicaltrials.gov) - Jan 26, 2014
P3, N=763, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed Recruiting --> Active, not recruiting
- ||||||| Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
Trial completion: NVA237 Versus Placebo 12-week Efficacy Study (clinicaltrials.gov) - Jan 13, 2014
P3, N=440, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- || Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
Trial suspension: Efficacy of NVA237 (50 μg o.d) Using Tiotropium (5μg μg o.d) as Active Control in COPD Patients. (clinicaltrials.gov) - Jan 12, 2014
P3, N=340, Suspended, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Not yet recruiting --> Suspended
- | Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
Trial initiation date: Efficacy of NVA237 (50 μg o.d) Using Tiotropium (5μg μg o.d) as Active Control in COPD Patients. (clinicaltrials.gov) - Jan 12, 2014
P3, N=340, Suspended, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Suspended Initiation date: Oct 2013 --> Apr 2014
- |||| Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
Enrollment open: Efficacy of NVA237 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD) (clinicaltrials.gov) - Sep 23, 2013
P4, N=150, Recruiting, Sponsor: Novartis Pharmaceuticals
Initiation date: Oct 2013 --> Apr 2014 Not yet recruiting --> Recruiting
- Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
Trial withdrawal: GLOW8: Safety and Efficacy of NVA237 as an add-on to Fixed Dose Combination LABA/ICS (clinicaltrials.gov) - Aug 25, 2013
P3, N=0, Withdrawn, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Not yet recruiting --> Withdrawn
- Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
Enrollment change: GLOW8: Safety and Efficacy of NVA237 as an add-on to Fixed Dose Combination LABA/ICS (clinicaltrials.gov) - Aug 25, 2013
P3, N=0, Withdrawn, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Withdrawn N=1120 --> 0
- ||||| Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
Enrollment change: GLOW5: Efficacy, Safety, and Tolerability of NVA237 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD) (clinicaltrials.gov) - Aug 25, 2013
P3, N=657, Completed, Sponsor: Novartis Pharmaceuticals
N=1120 --> 0 N=980 --> 657
- ||||| Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei, Onbrez (indacaterol) / Novartis
Enrollment change: GLOW6: Efficacy, Safety and Tolerability of the Co-administration of NVA237 Plus Indacaterol Once Daily Versus Indacaterol Once Daily in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (clinicaltrials.gov) - Aug 20, 2013
P3, N=445, Completed, Sponsor: Novartis Pharmaceuticals
N=980 --> 657 N=671 --> 445
- ||||| Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
New P4 trial: Efficacy of NVA237 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD) (clinicaltrials.gov) - Aug 12, 2013
P4, N=150, Recruiting, Sponsor: Novartis Pharmaceuticals
- ||||||| Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
Trial completion: Efficacy, Safety and Tolerability of NVA237 in Patients With Chronic Obstructive Pulmonary Disease (clinicaltrials.gov) - Jul 30, 2013
P3, N=458, Completed, Sponsor: Novartis Pharmaceuticals
N=671 --> 445 Recruiting --> Completed
- ||| Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
New P3 trial: Efficacy of NVA237 (50 μg o.d) Using Tiotropium (5μg μg o.d) as Active Control in COPD Patients. (clinicaltrials.gov) - Apr 21, 2013
P3, N=340, Suspended, Sponsor: Novartis Pharmaceuticals
- ||||||| Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei, Onbrez (indacaterol) / Novartis
Trial completion: GLOW6: Efficacy, Safety and Tolerability of the Co-administration of NVA237 Plus Indacaterol Once Daily Versus Indacaterol Once Daily in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (clinicaltrials.gov) - Mar 24, 2013
P3, N=445, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed Recruiting --> Completed
- ||||||| Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
Trial completion: GLOW5: Efficacy, Safety, and Tolerability of NVA237 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD) (clinicaltrials.gov) - Mar 13, 2013
P3, N=657, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed Recruiting --> Completed
- Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
Trial initiation date: GLOW8: Safety and Efficacy of NVA237 as an add-on to Fixed Dose Combination LABA/ICS (clinicaltrials.gov) - Feb 10, 2013
P3, N=0, Withdrawn, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed Initiation date: Jan 2013 --> Apr 2013
- Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
New P3 trial: GLOW8: Safety and Efficacy of NVA237 as an add-on to Fixed Dose Combination LABA/ICS (clinicaltrials.gov) - Dec 26, 2012
P3, N=0, Withdrawn, Sponsor: Novartis Pharmaceuticals
- ||||| Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
Enrollment change: GLOW4: Long Term Safety and Tolerability of NVA237 Versus Tiotropium in Japanese Patients (clinicaltrials.gov) - Dec 11, 2012
P3, N=211, Completed, Sponsor: Novartis Pharmaceuticals
Initiation date: Jan 2013 --> Apr 2013 N=160 --> 211
- |||||||||| Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
New P3 trial: NVA237 BID Versus Placebo Twelve-week Efficacy Study (clinicaltrials.gov) - Oct 24, 2012
P3, N=432, Completed, Sponsor: Novartis Pharmaceuticals
- |||||||||| Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
New P3 trial: NVA237 Versus Placebo 12-week Efficacy Study (clinicaltrials.gov) - Oct 16, 2012
P3, N=440, Completed, Sponsor: Novartis Pharmaceuticals
- |||||||||| Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
New P3 trial: GLOW5: Efficacy, Safety, and Tolerability of NVA237 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD) (clinicaltrials.gov) - Jun 5, 2012
P3, N=657, Completed, Sponsor: Novartis Pharmaceuticals
- | Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
New P1 trial: Comparing the Pharmacokinetics, Safety and Tolerability of NVA237 in Renal Impairment (clinicaltrials.gov) - Jun 5, 2012
P1, N=48, Completed, Sponsor: Novartis Pharmaceuticals
- |||||||||| Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei, Onbrez (indacaterol) / Novartis
New P3 trial: GLOW6: Efficacy, Safety and Tolerability of the Co-administration of NVA237 Plus Indacaterol Once Daily Versus Indacaterol Once Daily in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (clinicaltrials.gov) - May 21, 2012
P3, N=445, Completed, Sponsor: Novartis Pharmaceuticals
- ||||||| Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
Trial completion: GLOW4: Long Term Safety and Tolerability of NVA237 Versus Tiotropium in Japanese Patients (clinicaltrials.gov) - Apr 16, 2012
P3, N=211, Completed, Sponsor: Novartis Pharmaceuticals
N=160 --> 211 Active, not recruiting --> Completed
- |||||||||| Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
New P3 trial: Efficacy, Safety and Tolerability of NVA237 in Patients With Chronic Obstructive Pulmonary Disease (clinicaltrials.gov) - Mar 27, 2012
P3, N=458, Completed, Sponsor: Novartis Pharmaceuticals
- ||||| Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
Enrollment change: GLOW 1: A Study to Assess the Safety, Tolerability and Efficacy of NVA237 Versus Placebo (clinicaltrials.gov) - Mar 14, 2012
P3, N=1324, Completed, Sponsor: Novartis
Active, not recruiting --> Completed N=800 --> 1324
- | firtecan pegol (PEG-SN38) / Belrose
Enrollment closed: Study of EZN-2208 Pediatric Patients With Solid Tumors (clinicaltrials.gov) - Mar 6, 2012
P1/2, N=24, Active, not recruiting, Sponsor: Enzon Pharmaceuticals, Inc.
N=800 --> 1324 Recruiting --> Active, not recruiting
- |||||||||| Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
New P3 trial: Efficacy, Tolerability and Safety of NVA237 in Patients With Chronic Obstructive Pulmonary Disease (clinicaltrials.gov) - Jan 18, 2012
P3, N=763, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
- ||| firtecan pegol (PEG-SN38) / Belrose
Enrollment closed, Metastases: PEG-SN38: A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer (clinicaltrials.gov) - Sep 18, 2011
P2, N=160, Active, not recruiting, Sponsor: Enzon Pharmaceuticals, Inc.
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting